Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2104 • ACR Convergence 2022
The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE
Jennifer Rogers¹, Amanda Eudy², Roberta Alexander³, David Pisetsky⁴, John Conklin³, Kai Sun⁵, Lisa Criscione-Schreiber⁶, Jayanth Doss⁵, Rebecca Sadun⁵, Mithu Maheswaranathan¹ and Megan Clowse⁵, ¹Duke, Durham, NC, ²Duke University, Raleigh, NC, ³Exagen, Inc., Vista, CA, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Duke University School of Medicine, Durham, NC
Background/Purpose: Manifestations of SLE can be divided into two subtypes. Type 1 SLE includes classic SLE manifestations that are driven by autoimmune inflammatory mechanisms. Type…
Abstract Number: 2265 • ACR Convergence 2022
Autoimmune RNA Dysregulation and Seizures: Therapeutic Prospects in Neuropsychiatric Systemic Lupus Erythematosus
Henri Tiedge¹, ILHAM MUSLIMOV², Valerio Berardi², Stacy Stephenson³, Ellen M. Ginzler⁴, Anca Askanase⁵ and John Hanly⁶, ¹SUNY, Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Medical Center, Brooklyn, NY, ³SUNY Downstate Medical Center, dep. of Comparative Medicine, Brooklyn, NY, ⁴SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ⁵Columbia University Medical Center, New York, NY, ⁶Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Neuropsychiatric (NP) involvement is common in systemic lupus erythematosus (SLE). Manifestations often include seizures and cognitive impairment but underlying etiology remains poorly understood. Brain…
Abstract Number: 0074 • ACR Convergence 2022
Real-World Treatment Patterns, Healthcare Resource Utilization (HCRU) and Costs in Patients with Systemic Lupus Erythematosus (SLE) in the US
Prajakta Masurkar¹, Jennifer Reckleff², Nicole Princic³, Brendan Limone⁴, Hana Schwartz⁴, Elaine Karis⁵, Eric Zollars⁶, Bradley Stolshek⁵ and Karen Costenbader⁷, ¹Amgen, Wylie, TX, ²Amgen, Westlake Village, CA, ³IBM Watson Health, Reading, MA, ⁴IBM Watson Health, Bethesda, MD, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Amgen, Newbury Park, CA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: SLE treatment is complex, with a wide variety of medications commonly prescribed. Limited evidence exists in the literature with respect to treatment patterns, HCRU…
Abstract Number: 0190 • ACR Convergence 2022
Effect of Shared Decision-making on Trust in Physician in the Clinical Practice of Systemic Lupus Erythematosus: The TRUMP2-SLE Study
Ryusuke Yoshimi¹, Chiharu Hidekawa², Natsuki Sakurai³, Nobuyuki Yajima⁴, Noriaki Kurita⁵, Naoki Suzuki³, Yuji Yoshioka³, Daiga Kishimoto⁶, Noriko Kojitani³, Yumiko Sugiyama³, Yosuke Kunishita⁷, Kana Higashitani³, Yuji Uzawa³, Yuichiro Sato³, Soichiro Adachi³, Yuki Iizuka³, Ayaka Maeda³, Lisa Hirahara³, Takaaki Komiya³, Yutaro Soejima³, Naoki Hamada³, Hideto Nagai³, Naomi Tsuchida³, Kaoru Takase-Minegishi³, Yohei Kirino³, Nao Oguro⁴, Keigo Hayashi⁸, Kenta Shidahara⁸, Yoshia Miyawaki⁸, Ken-ei Sada⁹, Dai Kishida¹⁰, Takanori Ichikawa¹¹, Yasuhiro Shimojima¹⁰, Yuichi Ishikawa¹², Shigeru Ohno¹³ and Hideaki Nakajima³, ¹Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Kanazawa Ward, Yokohama Kanagawa, Japan, ²Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama City, Kanagawa Prefecture, Japan, ³Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, ⁴Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ⁵Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University, Fukushima, Japan, ⁶Center for Rheumatic Diseases, Yokohama City University Medical Center, Kanazawa-ku Yokohamashi, Japan, ⁷Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Kanagawa, Japan, ⁸Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁹Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Okayama, Japan, ¹⁰Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ¹¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, ¹²First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ¹³Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: In recent years, one of the overarching principles of EULAR recommendation is that systemic lupus erythematosus (SLE) treatment should be based on shared decision-making…
Abstract Number: 0333 • ACR Convergence 2022
Autoantibody Trajectories Associate with Classification and Treatment Response in Lupus Nephritis
Andrea Fava¹, Carla J. Guthridge², Joseph Kheir², Catriona Wagner³, Michelle Petri⁴, Jill Buyon⁵, Betty Diamond⁶, the Accelerating Medicines Partnership (AMP) RA/SLE⁷, Joel Guthridge² and Judith James², ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma, ⁴Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Multiple Insitutions
Background/Purpose: Autoantibodies are a hallmark of lupus nephritis (LN). While there is known heterogeneity in autoantibody expression among LN patients, the association of autoantibodies with…
Abstract Number: 0350 • ACR Convergence 2022
Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
Vicente Aldasoro¹, María Laiño¹, Monica Enguita¹, Santos Castañeda², Javier Loricera³, Carmen Lasa-Teja⁴, Clara Moriano⁵, Vanesa Calvo Río⁶, Ivette Casafont-Solé⁷, Judit Font Urgelles⁷, Patricia Quiroga-Colina⁸, Samuel Hernandez⁹, Sergi Heredia¹⁰, A. Garcia-Aparicio¹¹, Joaquin Maria Belzunegui Otano¹², Aaron Fariña¹³, Francisco Javier Navarro Blasco¹⁴, Patricia Fanlo Mateo¹, Adela Gallego¹⁵, Juan M Blanco Madrigal¹⁶, María Ángeles Matías¹⁷, Cilia Peralta¹⁸, Jordi Camins-Fàbregas¹⁹, Marcos Paulino²⁰, Ana Urruticoechea²¹, Piter Jose Cossio Jimenez²², Miguel Medina Malone²³, Eva Perez Pampin²⁴, Rafaela Ortega-Castro²⁵, Blanca varas de Dios²⁶, Jose Ramon Lamua Riazuelo²⁷ and Emilio Jose Giner²⁸, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Complejo Asistencial Universitario de León, León, Spain, ⁶Valdecilla Hospital, Santander, Spain, ⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁸Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁹Hospital Son Llàtzer, Palma de Mallorca, Spain, ¹⁰Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despi, Spain, ¹¹Hospital Universitario de Toledo, Toledo, Spain, ¹²Hospital Universitario de Donostia, Donostia-San Sebasti, Spain, ¹³Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹⁴Hospital General Universitario de Elche, Elche, Spain, ¹⁵Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹⁶Basurto University Hospital, Bilbao, Spain, ¹⁷Hospital Universitario Infanta Leonor, Madrid, Spain, ¹⁸Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹⁹Hospital General de Granollers, Granollers, Spain, ²⁰Hospital General Universiario de Ciudad Real, Ciudad Real, Spain, ²¹Hospital Can Misses, Ibiza, Spain, ²²Hospital Reina Sofia, Tudela, Spain, ²³Hospital Calahorra, Calahorra, Spain, ²⁴Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Cordoba, Spain, ²⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²⁶Santa Cristina Hospital, Madrid, Spain, ²⁷Hospital Universitario del Henares, Madrid, Spain, ²⁸Hospital Royo Villanova, Zaragoza, Spain
Background/Purpose: To describe demographic characteristics, efficacy and safety of BLM since its approval in SLE patients in a real-world setting. Methods: Descriptive, retrospective, multicenter study…
Abstract Number: 0514 • ACR Convergence 2022
Renal Response Outcomes of North American Youth with Proliferative Lupus Nephritis Treated with the EuroLupus versus NIH Cyclophosphamide Dosing Regimen
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy P Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹⁰, Kelly Rouster-Stevens¹¹, Aliese Sarkissian¹², Julia Shalen¹³, William Soulsby¹⁴, Marinka Twilt¹⁵, Eveline Wu¹⁶, Laura Lewandowski¹⁷, Scott Wenderfer¹⁸ and Jennifer Cooper¹⁹, ¹Children's Hospital of Colorado/University of Colorado, Denver, CO, ²Duke University, Durham, NC, ³University of Colorado School of Medicine, Aurora, CO, ⁴Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Division of Pediatric Rheumatology, Department of Pediatrics, Emory University School of Medicine; Children’s Healthcare of Atlanta, Atlanta, GA, ¹²University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴University of California, San Francisco, San Francisco, CA, ¹⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹⁶University of North Carolina, Chapel Hill, NC, ¹⁷NIAMS, NIH, Bethesda, MD, ¹⁸British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁹Children's Hospital of Colorado/University of Colorado, Aurora, CO
Background/Purpose: There have been no published studies comparing renal outcomes of youth with proliferative lupus nephritis (LN) treated with the lower-dose EuroLupus (EL) cyclophosphamide (CYC)…
Abstract Number: 0637 • ACR Convergence 2022
Reduced IgG Sialic Acid Content: A Distinctive Characteristic of Symptomatic Anti-Nuclear Antibodies Positive Individuals
Carolina Munoz¹, Sindu Johnson², Zahi Touma¹, Zareen Ahmad², Dennisse Bonilla¹, Linda Hiraki³, Arthur Bookman² and Joan Wither⁴, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Currently the immune changes that lead to the transition from asymptomatic Anti-Nuclear Antibody (ANA) positivity to symptomatic disease are unknown. Studies in our laboratory…
Abstract Number: 0657 • ACR Convergence 2022
DB-2304, a Novel anti-BDCA2 Monoclonal Antibody Drug Conjugate, Displayed Great Potency in Suppression of pDC Functions
Xi Li, Yu Zhang, Bing Li and Haiqing Hua, Duality Biologics, Shanghai, China
Background/Purpose: BDCA2 (Blood Dendritic Cell Antigen 2) is specifically expressed on plasmacytoid dendritic cells (pDCs), a type I interferon-producing cells, which have been implicated in…
Abstract Number: 0745 • ACR Convergence 2022
Use of Telemedicine in Patients with Systemic Lupus Erythematosus in a Publicly Funded Hospital System
Sebastian Bruera¹, Kristen Staggers¹, Maria Suarez-Almazor² and Sandeep Agarwal¹, ¹Baylor College of Medicine, Houston, TX, ²MD Anderson Cancer Center, Houston, TX
Background/Purpose: The coronavirus disease 2019 (COVID-19) pandemic caused a widespread and emergent use of telemedicine outpatient visits to avoid patient exposure to the SARS-CoV-2 virus.…
Abstract Number: 0961 • ACR Convergence 2022
The Use of Belimumab Before and During Pregnancy in Patients with Systemic Lupus Erythematosus: An Italian Multicenter Case-series
Francesca Crisafulli¹, MARIA CHIARA GERARDI², Maria Letizia Urban³, Margherita Zen⁴, Melissa Padovan⁵, Valentina Canti⁶, Emanuela Praino⁷, Cecilia Nalli¹, Francesca Ruffilli⁵, Francesca Saccon⁸, Micaela Fredi⁹, Liala Moschetti¹, Giacomo Emmi³, Luca Iaccarino⁴, Andrea Doria¹⁰, Leonardo Santo⁷, Franco Franceschini¹, Laura Andreoli¹ and Angela Tincani¹¹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia and Rheumatology Unit, ASST G.O.M. Niguarda, Milan, Milano, Italy, ³Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁴Unit of Rheumatology, Department of Medicine, University of Padova, Padova, Italy, ⁵Rheumatology Unit, Azienda Ospedaliero-Universitaria of Ferrara, Ferrara, Italy, ⁶Division of Immunology, IRCCS San Raffaele Institute, Milano, Italy, ⁷Rheumatology Unit, Presidio Ospedaliero ‘Mons. Dimiccoli’, Barletta, Italy, ⁸Unit of Rheumatology, Department of Medicine, University of Padova and Fondazione Villa Salus, Mestra, Venezia, Italy, ⁹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Manerbio, Italy, ¹⁰Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Via Giustiniani, 2, 35128 Padova, Italy., Padova, Italy, ¹¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Gussago, Italy
Background/Purpose: Belimumab (BEL) is an anti-BLyS monoclonal antibody approved for SLE treatment. As few data about BEL use with regard to pregnancy are available, the…
Abstract Number: 0982 • ACR Convergence 2022
Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression and Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Jordan Jacquez¹, Lisa Zhu¹, Manpreet Singh¹, Caroline Siegel², Lori Sahakian¹, Brian Skaggs¹, Jennifer Grossman¹ and Maureen McMahon¹, ¹University of California Los Angeles, Los Angeles, CA, ²Hospital for Special Surgery, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) has demonstrated benefit in multiple outcomes in systemic lupus erythematosus (SLE), including disease activity, flare rates, survival, and thrombotic events. Previous studies,…
Abstract Number: 0999 • ACR Convergence 2022
Differences in Chromatin Accessibility Pre- and Post-Induction Therapy in Pediatric Lupus
Joyce Hui-Yuen¹, Kaiyu Jiang², Susan Malkiel³, Betty Diamond³ and James Jarvis⁴, ¹North Shore LIJ Health System, Great Neck, NY, ²University at Buffalo, Buffalo, NY, ³Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Department of Pediatrics, University at Buffalo Clinical and Translational Research Center, Buffalo, NY
Background/Purpose: Systemic lupus erythematosus (SLE) may be triggered by gene-environment interactions. Data are scarce on how epigenetic variance contributes to disease risk in pediatric SLE…
Abstract Number: 1186 • ACR Convergence 2022
The Trajectory of Multimorbidity in Patients with Systemic Lupus Erythematosus in the United States
Ali Duarte-Garcia¹, Maria Stevens², Herbert Heien², Gabriel Figueroa Parra¹, Jose A Meade-Aguilar¹, Molly M. Jeffery², Uma Thanarajasingam¹, Cynthia Crowson³ and Rozalina McCoy², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Eyota, MN
Background/Purpose: The presence of multiple chronic conditions (multimorbidity) is associated with disability and premature death. We determined the trajectory of multimorbidity in SLE compared to…
Abstract Number: 1360 • ACR Convergence 2022
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy P Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹⁰, Kelly Rouster-Stevens¹¹, Aliese Sarkissian¹², Julia Shalen¹³, William Soulsby¹⁴, Marinka Twilt¹⁵, Eveline Wu¹⁶, Laura Lewandowski¹⁷, Scott Wenderfer¹⁸ and Jennifer Cooper¹⁹, ¹Children's Hospital of Colorado/University of Colorado, Denver, CO, ²Duke University, Durham, NC, ³University of Colorado School of Medicine, Aurora, CO, ⁴Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹²University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴University of California, San Francisco, San Francisco, CA, ¹⁵Alberta Children's Hospital, Calgary, AB, Canada, ¹⁶University of North Carolina, Chapel Hill, NC, ¹⁷NIAMS, NIH, Bethesda, MD, ¹⁸British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁹University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].